
Estradiol (topical application route) - Mayo Clinic
Mar 1, 2025 · Although appropriate studies on the relationship of age to the effects of estradiol topical emulsion have not been performed in the geriatric population, no geriatric-specific …
Estradiol (vaginal route) - Mayo Clinic
Mar 1, 2025 · Description. Estradiol vaginal . gel, insert, and ring are used to treat changes in and around the vagina (such as vaginal dryness, itching, and burning) caused by low estrogen …
Estradiol and progesterone (oral route) - Mayo Clinic
Description. Estradiol and progesterone combination is used to treat moderate to severe symptoms of menopause (eg, feelings of warmth in the face, neck, and chest, or sudden …
Estradiol (transdermal route) - Mayo Clinic
Mar 1, 2025 · Description. Estradiol . transdermal gel, patch, and spray are used to treat moderate to severe symptoms of menopause (eg, feelings of warmth in the face, neck, and chest, or …
Bioidentical hormones: Are they safer? - Mayo Clinic
Oct 3, 2024 · No, they aren't. The hormones marketed as "bioidentical" and "natural" aren't safer than hormones used in traditional hormone therapy.
Estrogen (vaginal route) - Mayo Clinic
Mar 1, 2025 · Estrace. Estring. Femring. Imvexxy. Ortho Dienestrol. Premarin. Premarin Vaginal. Vagifem
Vaginal atrophy - Diagnosis & treatment - Mayo Clinic
Sep 17, 2021 · Systemic estrogen therapy. If vaginal dryness is associated with other symptoms of menopause, such as moderate or severe hot flashes, your doctor may suggest estrogen …
Feminizing hormone therapy - Mayo Clinic
Jul 12, 2024 · Why it's done. Feminizing hormone therapy is used to change the body's hormone levels. Those hormone changes trigger physical changes that help better align the body with a …
Atrofia vaginal - Diagnóstico y tratamiento - Mayo Clinic
Sep 17, 2021 · Para tratar el síndrome genitourinario en la menopausia, el médico puede recomendar primero opciones de tratamiento de venta libre, incluidos los siguientes: …
Prochlorperazine (oral route) - Mayo Clinic
Mar 1, 2025 · Appropriate studies performed to date have not demonstrated pediatric-specific problems that would limit the usefulness of prochlorperazine in children 2 years of age and …